GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (NAS:DOMH) » Definitions » Cyclically Adjusted PS Ratio

Dominari Holdings (Dominari Holdings) Cyclically Adjusted PS Ratio : 0.22 (As of Jun. 07, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Dominari Holdings Cyclically Adjusted PS Ratio?

As of today (2024-06-07), Dominari Holdings's current share price is $2.09. Dominari Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $9.43. Dominari Holdings's Cyclically Adjusted PS Ratio for today is 0.22.

The historical rank and industry rank for Dominari Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

DOMH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.17   Med: 2.7   Max: 109.89
Current: 0.23

During the past years, Dominari Holdings's highest Cyclically Adjusted PS Ratio was 109.89. The lowest was 0.17. And the median was 2.70.

DOMH's Cyclically Adjusted PS Ratio is ranked better than
94.46% of 505 companies
in the Biotechnology industry
Industry Median: 5.46 vs DOMH: 0.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dominari Holdings's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.228. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $9.43 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dominari Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Dominari Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Cyclically Adjusted PS Ratio Chart

Dominari Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 - - - 0.27

Dominari Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.25 0.20 0.27 0.26

Competitive Comparison of Dominari Holdings's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Dominari Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dominari Holdings's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Cyclically Adjusted PS Ratio falls into.



Dominari Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Dominari Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.09/9.43
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dominari Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dominari Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.228/131.7762*131.7762
=0.228

Current CPI (Mar. 2024) = 131.7762.

Dominari Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.250 100.560 0.328
201409 0.100 100.428 0.131
201412 0.048 99.070 0.064
201503 0.095 99.621 0.126
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 1.107 99.792 1.462
201603 1.946 100.470 2.552
201606 4.023 101.688 5.213
201609 5.414 101.861 7.004
201612 4.687 101.863 6.063
201703 4.809 102.862 6.161
201706 4.507 103.349 5.747
201709 3.783 104.136 4.787
201712 3.302 104.011 4.183
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.237 105.998 0.295
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.044 108.420 0.053
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.015 128.729 0.015
202309 0.180 129.860 0.183
202312 0.185 129.419 0.188
202403 0.228 131.776 0.228

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dominari Holdings  (NAS:DOMH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Dominari Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dominari Holdings (Dominari Holdings) Business Description

Traded in Other Exchanges
Address
One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Executives
Kyle Michael Wool director 650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall officer: Chief Operating Officer DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Anthony Hayes director, officer: Chief Executive Officer 1796 SHADY LANE, COLUMBIA SC 29206
George Way officer: Chief Financial Officer C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick director 10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner director ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley director ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander director 913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg director 781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner officer: Interim CFO 6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon director 6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen officer: Chief Financial Officer C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002